Stacey B Trooskin - Faculty Biosketch

Stacey B Trooskin, MD, PhD, MPH

Clinical Assistant Professor of Medicine (Infectious Diseases)

Attending Physician, Penn Presbyterian Medical Center

Department: Medicine

Contact information

Philadelphia Fight
1233 Locust Street
Philadelphia, PA 19107

Education:
BS (Biology)
University of Pennsylvania, 1998.
MPH (Epidemiology of Microbial Disease)
Yale University, School of Epidemiology and Public Health, 2001.
PhD (Epidemiology)
Rutgers School of Public Health, 2005.
MD
University of Medicine and Dentistry of New Jersey Robert Wood Johnson School of Medicine , 2007.

Post-Graduate Training
Residency in Internal Medicine, Hospital of the University of Pennsylvania, 2007-2010.
Fellowship in Infectious Diseases, Hospital of the University of Pennsylvania, 2010-2012.

Certifications
Internal Medicine, 2012.
Infectious Diseases, 2014.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Jhaveri R and Trooskin SB: Conversations with the editors: Hepatitis c virus—Where are we now and where do we go from here? Clinical Therapeutics August 2020.

G J Dore & S. Trooskin: People with Hepatitis C Who Inject Drugs - Underserved, Not Undeserving. New England Journal of Medicine 383(7): 608, august 2020.

CS Graham & S. Trooskin: Universal Screening for Hepatitis C Virus Infection: A Step Toward Elimination. JAMA March 2020.

Spaulding AC, Graham CS, Akiyama MJ, Chhatwal J, Nijhawan AE, Ninburg MH, Rich JD, Strick LB, Taylor LE, Trooskin SB, Westergaard RP, Sabol WJ: Letter to the Editor: Hepatitis C Virus Prevalence Estimates Among Incarcerated Persons. Hepatology 70(2): 758-759, Aug 2019.

Day E, Broder T, Bruneau J, Cruse S, Dickie M, Fish S, Grillon C, Luhmann N, Mason K, McLean E, Trooskin S, Treloar C, Grebely J: Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. Int J Drug Policy 66: 87-93, May 2019.

Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J, International Network on Hepatitis in Substance Users (INHSU): Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int 39(1): 20-30, Jan 2019.

Ramers CB, Trooskin SB: Hepatitis C Virus in the Modern Direct-Acting Antiviral Era: Where Have All the Special Populations Gone? Clin Liver Dis 12(5): 143-149, Nov 2018.

Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, Lo Re V 3rd: Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. Open Forum Infect Dis 5(6): ofy076, Jun 2018.

Graham CS, Trooskin SB: Removing the Barriers from the Path to Eliminate Hepatitis C. Infect Dis Clin North Am 32(2): xv-xvi, Jun 2018.

Kushner T, Shaw PA, Kalra A, Magaldi L, Monpara P, Bedi G, Krok K, Centkowski S, Dalldorf K, D'souza J, Halegoua-De Marzio D, Goldberg DS, Trooskin S, Levine LD, Srinivas SK, Lewis JD, Forde KA, Lo Re V: Incidence, determinants and outcomes of pregnancy-associated hepatitis B flares: A regional hospital-based cohort study. Liver Int 38(5): 813-820, May 2018.